Clinical trials: Bladder Cancer Requiring Cystectomy, open to volunteers
Bladder Cancer Requiring Cystectomy, Ileal Conduit
A Feasibility Randomized Trial Evaluating Early vs Late Stent Removal Following Radical Cystectomy and Ileal Conduit Formation for Bladder Cancer
Bladder cancer is the 4th most common cancer in men and 5th most common type of cancer in Canada. Urothelial cancer accounts for approximately 90% of malignancies.
- Conditions
- Bladder Cancer Requiring Cystectomy, Ileal Conduit, Urinary Diversion
- Trial name
- STENT-OPT (NCT06595446)
- Testing
- Early Stent removal, Late Stent removal
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Western University, Canada
Cystectomy, Bladder Cancer Requiring Cystectomy
Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis
The aim of this trial is to test whether postoperative antibiotics targeted towards bacteria in the urine can reduce the risk of infection after surgical removal of the bladder (cystectomy) compared to a standardised antibiotic…
- Conditions
- Cystectomy, Bladder Cancer Requiring Cystectomy, Postoperative Infections, Antibiotic Prophylaxis
- Trial name
- REINFORCE (NCT06709196)
- Testing
- Pivmecillinam, Amoxicillin clavulanic acid, Amoxicillin
- Where
- 5 sites in Denmark
- Volunteers
- 248 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Bladder Cancer Requiring Cystectomy, Erectile Dysfunction Following Radical Prostatectomy
Pilot Study of a New Nerve Grafting Method During Bladder Cancer Surgery to Help Preserve Erections.
This pilot study will evaluate the safety and 1-year erectile function recovery in 10 patients undergoing a novel Nerve Restoring Radical Cystectomy (NR-RC), which includes a genitofemoral nerve graft.
- Trial name
- NR-RC (NCT07140588)
- Testing
- Patients undergoing radical cystectomy will receive a novel NR-RC procedure using a genitofemoral nerve graft to enhance erectile function recovery.
- Volunteers
- 10 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Requiring Cystectomy
Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer
The TEMPO-MIBC trial is a phase III, single-center, two-arm, randomized, controlled trial. Its primary objective is to evaluate the efficacy of a simplified diagnostic and treatment pathway for muscle-invasive bladder cancer…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Requiring Cystectomy, Bladder Carcinoma, Bladder Neoplasm
- Trial name
- TEMPO-MIBC (NCT07067749)
- Testing
- multiparametric magnetic resonance imaging (mpMRI) of the bladder, Transurethral resection of bladder tumour (TURBt), Circulating tumour DNA levels assessment
- Where
- Italy
- Volunteers
- 92 people
- Sponsor
- University of Rome Tor Vergata